Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Enlivex ( (ENLV) ) has provided an announcement.
On March 23, 2026, Enlivex completed a $21 million senior secured convertible note financing with The Lind Partners, yielding about $18.7 million in net proceeds and convertible into ordinary shares at $2.69175, a hefty premium to its recent Nasdaq price. The structure gives Enlivex non-interest-bearing funding absent default and flexibility to repay partly in stock, while pledging its digital asset accounts, including its RAIN token portfolio, as first-priority collateral and imposing covenants that restrict additional indebtedness and certain equity-linked financings.
The company also expanded its prediction markets treasury moves, exercising part of its option to buy about 3.03 billion additional RAIN tokens for $10 million at a 62% discount to the March 22, 2026 closing price, and securing an extension of its option to buy up to roughly 272.1 billion more tokens at the same price through December 31, 2027. Enlivex’s board on March 15, 2026 approved a share repurchase program of up to $20 million of its ordinary shares, signaling management’s view that the stock trades below the value of its treasury and related assets and positioning the company to use its new financing and digital asset strategy to pursue both operational funding and potential shareholder value creation.
The most recent analyst rating on (ENLV) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Enlivex stock, see the ENLV Stock Forecast page.
Spark’s Take on ENLV Stock
According to Spark, TipRanks’ AI Analyst, ENLV is a Neutral.
The score is held down mainly by weak financial performance (no revenue, ongoing losses, and persistent cash burn despite improvement) and a valuation profile dominated by negative earnings. Technicals provide partial support due to a clear uptrend, but overbought momentum readings add near-term risk.
To see Spark’s full report on ENLV stock, click here.
More about Enlivex
Enlivex Ltd., based in Nes-Ziona, Israel, is a “quality longevity” company developing Allocetra™, a clinical-stage immunotherapy targeting inflammatory conditions associated with aging, with a primary focus on age-related osteoarthritis. Alongside its drug development, Enlivex runs a prediction markets treasury strategy centered on the RAIN protocol, a leading decentralized prediction markets infrastructure on the Arbitrum blockchain, giving the company exposure to the emerging digital asset ecosystem.
Average Trading Volume: 342,608
Technical Sentiment Signal: Sell
Current Market Cap: $263.5M
Find detailed analytics on ENLV stock on TipRanks’ Stock Analysis page.